Literature DB >> 11264158

Induction of cytotoxic T lymphocyte and antibody responses to enhanced green fluorescent protein following transplantation of transduced CD34(+) hematopoietic cells.

M Rosenzweig1, M Connole, R Glickman, S P Yue, B Noren, M DeMaria, R P Johnson.   

Abstract

Genetic modification of hematopoietic stem cells often results in the expression of foreign proteins in pluripotent progenitor cells and their progeny. However, the potential for products of foreign genes introduced into hematopoietic stem cells to induce host immune responses is not well understood. Gene marking and induction of immune responses to enhanced green fluorescent protein (eGFP) were examined in rhesus macaques that underwent nonmyeloablative irradiation followed by infusions of CD34(+) bone marrow cells transduced with a retroviral vector expressing eGFP. CD34(+) cells were obtained from untreated animals or from animals treated with recombinant human granulocyte colony-stimulating factor (G-CSF) alone or G-CSF and recombinant human stem cell factor. Levels of eGFP-expressing cells detected by flow cytometry peaked at 0.1% to 0.5% of all leukocytes 1 to 4 weeks after transplantation. Proviral DNA was detected in 0% to 17% of bone marrow--derived colony-forming units at periods of 5 to 18 weeks after transplantation. However, 5 of 6 animals studied demonstrated a vigorous eGFP-specific cytotoxic T lymphocyte (CTL) response that was associated with a loss of genetically modified cells in peripheral blood, as demonstrated by both flow cytometry and polymerase chain reaction. The eGFP-specific CTL responses were MHC-restricted, mediated by CD8(+) lymphocytes, and directed against multiple epitopes. eGFP-specific CTLs were able to efficiently lyse autologous CD34(+) cells expressing eGFP. Antibody responses to eGFP were detected in 3 of 6 animals. These data document the potential for foreign proteins expressed in CD34(+) hematopoietic cells and their progeny to induce antibody and CTL responses in the setting of a clinically applicable transplantation protocol. (Blood. 2001;97:1951-1959)

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11264158     DOI: 10.1182/blood.v97.7.1951

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  40 in total

1.  Nonmyeloablative conditioning regimen to increase engraftment of gene-modified hematopoietic stem cells in young rhesus monkeys.

Authors:  Alice F Tarantal; Francesca Giannoni; C Chang I Lee; Jennifer Wherley; Teiko Sumiyoshi; Michele Martinez; Christoph A Kahl; David Elashoff; Stan G Louie; Donald B Kohn
Journal:  Mol Ther       Date:  2012-01-31       Impact factor: 11.454

2.  In vivo eradication of MLL/ENL leukemia cells by NK cells in the absence of adaptive immunity.

Authors:  J Nakata; K Nakano; A Okumura; Y Mizutani; H Kinoshita; M Iwai; K Hasegawa; S Morimoto; F Fujiki; N Tatsumi; H Nakajima; Y Nakae; S Nishida; A Tsuboi; Y Oji; Y Oka; H Sugiyama; A Kumanogoh; N Hosen
Journal:  Leukemia       Date:  2013-11-13       Impact factor: 11.528

3.  Immunohistochemical toolkit for tracking and quantifying xenotransplanted human stem cells.

Authors:  Justine Allard; Ké Li; Xavier Moles Lopez; Stéphane Blanchard; Paul Barbot; Sandrine Rorive; Christine Decaestecker; Roland Pochet; Delphine Bohl; Angelo C Lepore; Isabelle Salmon; Charles Nicaise
Journal:  Regen Med       Date:  2014       Impact factor: 3.806

4.  Animal models for medical countermeasures to radiation exposure.

Authors:  Jacqueline P Williams; Stephen L Brown; George E Georges; Martin Hauer-Jensen; Richard P Hill; Amy K Huser; David G Kirsch; Thomas J Macvittie; Kathy A Mason; Meetha M Medhora; John E Moulder; Paul Okunieff; Mary F Otterson; Michael E Robbins; James B Smathers; William H McBride
Journal:  Radiat Res       Date:  2010-04       Impact factor: 2.841

5.  Prolonged adherence of human immunodeficiency virus-derived vector particles to hematopoietic target cells leads to secondary transduction in vitro and in vivo.

Authors:  Yung-Wei Pan; Jarrad M Scarlett; Tammy T Luoh; Peter Kurre
Journal:  J Virol       Date:  2006-10-11       Impact factor: 5.103

6.  New lines of GFP transgenic rats relevant for regenerative medicine and gene therapy.

Authors:  S Remy; L Tesson; C Usal; S Menoret; V Bonnamain; V Nerriere-Daguin; J Rossignol; C Boyer; T H Nguyen; P Naveilhan; L Lescaudron; I Anegon
Journal:  Transgenic Res       Date:  2010-01-22       Impact factor: 2.788

7.  White paper on how to go forward with cell-based advanced therapies in Europe.

Authors:  Reinhold G Erben; Beatriz Silva-Lima; Ilona Reischl; Gustav Steinhoff; Gudrun Tiedemann; Wilfried Dalemans; Alexander Vos; Rob T A Janssen; Katarina Le Blanc; Gerjo J V M van Osch; Frank P Luyten
Journal:  Tissue Eng Part A       Date:  2014-06-03       Impact factor: 3.845

8.  Modeling promising nonmyeloablative conditioning regimens in nonhuman primates.

Authors:  Devikha Chandrasekaran; Betty Nakamoto; Korashon L Watts; Hans-Peter Kiem; Thalia Papayannopoulou
Journal:  Hum Gene Ther       Date:  2014-12       Impact factor: 5.695

9.  Cost-effective sequence-based nonhuman primate MHC class I genotyping from RNA.

Authors:  Julie A Karl; Roger W Wiseman; David H O'Connor
Journal:  Methods       Date:  2009-05-13       Impact factor: 3.608

10.  Transgene expression levels determine the immunogenicity of transduced hematopoietic grafts in partially myeloablated mice.

Authors:  Herena Eixarch; Alba Gómez; Elisabeth Kádár; Mónica George; Nuria Martínez; Carmen Espejo; Jordi Pétriz; Ramon Gimeno; Jordi Barquinero
Journal:  Mol Ther       Date:  2009-08-25       Impact factor: 11.454

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.